Suppr超能文献

使用PRECIS-2工具评估肺癌筛查随机试验的实用性

Evaluating Pragmatism of Lung Cancer Screening Randomized Trials with the PRECIS-2 Tool.

作者信息

Hirsch Erin A, Studts Jamie L, Zane Susan, McCreight Marina, Huebschmann Amy G

机构信息

From the Cancer Prevention Precision Control Institute, Cancer for Discovery & Innovation at Hackensack Meridian Health, Nutley, NJ, and University of Colorado School of Medicine, Department of Medicine, Division of Medical Oncology, Aurora, CO (EAH); Professor, Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, Co-Leader, Cancer Prevention and Control Program, University of Colorado Cancer Center, Aurora, CO (JLS); University of Colorado School of Medicine, Department of Family Medicine, Aurora, CO (SZ); Colorado School of Public Health, Department of Health Systems Management and Policy, Aurora, CO (MM); University of Colorado School of Medicine, Department of Medicine, Division of General Internal Medicine, Adult and Child Center for Outcomes Research and Delivery Science, Ludeman Family Center for Women's Health Research, Aurora, CO (AGH).

出版信息

J Am Board Fam Med. 2025 May 12;38(1):56-83. doi: 10.3122/jabfm.2024.240142R1.

Abstract

OBJECTIVE

Lung cancer screening (LCS) implementation has been challenging for community and rural primary care settings. One contributing factor may be that the randomized clinical trials (RCTs) that form the evidence base are guided by explanatory methods not reflective of primary care settings. This study applied the agmatic xplanatory ontinuum ndicator ummary (PRECIS - 2) tool to determine the pragmatism of LCS RCTs envisioned through a decentralized, primary care lens.

METHODS

LCS RCTs were identified from efficacy meta-analyses, and the VA Demonstration Project was chosen as a nonrandomized multi-center comparator case. Two independent raters evaluated PRECIS-2 domains for each trial. Ratings were completed on a 5-point scale, where 1 indicated completely explanatory and 5 indicated completely pragmatic. Mean PRECIS-2 scores were calculated for each study and each domain. Descriptive information from raters' comments was used to describe differences between the most pragmatic and most explanatory RCTs.

RESULTS

Eleven RCTs and the VA Demonstration Project were evaluated. Mean PRECIS-2 scores for each study ranged from 2.12 to 3.33, with the DLSCT rated the most explanatory and the Lung Screening Study and ITALUNG studies rated the most pragmatic. Six domains had a mean score <3, indicating more explanatory (eligibility, recruitment, setting, organization, staff flexibility, follow-up). The remaining 3 domains had mean scores >3, indicating more pragmatic (adherence, outcome, analysis).

DISCUSSION

This approach of evaluating each study from a primary care lens demonstrated that LCS RCTs trended toward a more explanatory nature, incorporating considerable support and infrastructure that extend beyond the capacity of typical primary care settings in the US.

摘要

目的

肺癌筛查(LCS)在社区和农村初级保健机构中的实施一直具有挑战性。一个促成因素可能是,构成证据基础的随机临床试验(RCT)是由无法反映初级保健机构情况的解释性方法所指导的。本研究应用务实-解释性连续体指标总结(PRECIS - 2)工具,从分散的初级保健视角来确定设想的LCS随机对照试验的务实程度。

方法

从疗效荟萃分析中识别出LCS随机对照试验,并选择退伍军人事务部示范项目作为非随机多中心对照案例。两名独立评估者对每项试验的PRECIS-2领域进行评估。评分采用5分制,1表示完全解释性,5表示完全务实性。计算每项研究和每个领域的平均PRECIS-2得分。评估者评论中的描述性信息用于描述最务实和最具解释性的随机对照试验之间的差异。

结果

对11项随机对照试验和退伍军人事务部示范项目进行了评估。每项研究的平均PRECIS-2得分在2.12至3.33之间,双低剂量螺旋CT(DLSCT)被评为最具解释性,肺癌筛查研究和意大利肺癌研究被评为最务实。六个领域的平均得分<3,表明更具解释性(入选标准、招募、环境、组织、人员灵活性、随访)。其余三个领域的平均得分>3,表明更务实(依从性、结局、分析)。

讨论

这种从初级保健视角评估每项研究的方法表明,LCS随机对照试验倾向于更具解释性,纳入了大量超出美国典型初级保健机构能力的支持和基础设施。

相似文献

1
Evaluating Pragmatism of Lung Cancer Screening Randomized Trials with the PRECIS-2 Tool.
J Am Board Fam Med. 2025 May 12;38(1):56-83. doi: 10.3122/jabfm.2024.240142R1.
6
Comments, suggestions, and criticisms of the Pragmatic Explanatory Continuum Indicator Summary-2 design tool: a citation analysis.
J Clin Epidemiol. 2024 Dec;176:111534. doi: 10.1016/j.jclinepi.2024.111534. Epub 2024 Sep 14.
8
Generalizability of randomized controlled trials in primary health care: Applying the PRECIS-2 tool on published protocols.
J Eval Clin Pract. 2023 Mar;29(2):253-262. doi: 10.1111/jep.13759. Epub 2022 Sep 7.
9
PRECIS-2 analysis of pragmatic acupuncture trials: a systematic review.
BMC Complement Med Ther. 2024 May 3;24(1):181. doi: 10.1186/s12906-024-04473-7.
10
Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades.
JAMA Cardiol. 2019 Nov 1;4(11):1122-1128. doi: 10.1001/jamacardio.2019.3604.

引用本文的文献

1
Research on the Social Context of Medicine and the Modern Family Physician.
J Am Board Fam Med. 2025 Jan-Feb;38(1):1-3. doi: 10.3122/jabfm.2024.240443R0.

本文引用的文献

1
2
3
Outcomes From More Than 1 Million People Screened for Lung Cancer With Low-Dose CT Imaging.
Chest. 2023 Jul;164(1):241-251. doi: 10.1016/j.chest.2023.02.003. Epub 2023 Feb 10.
4
Actual and Potential Role of Primary Care Physicians in Cancer Prevention.
Cancers (Basel). 2023 Jan 9;15(2):427. doi: 10.3390/cancers15020427.
5
Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.
Cochrane Database Syst Rev. 2022 Aug 3;8(8):CD013829. doi: 10.1002/14651858.CD013829.pub2.
6
Racial Disparities in Adherence to Annual Lung Cancer Screening and Recommended Follow-Up Care: A Multicenter Cohort Study.
Ann Am Thorac Soc. 2022 Sep;19(9):1561-1569. doi: 10.1513/AnnalsATS.202111-1253OC.
7
Guideline-Recommended Lung Cancer Screening Adherence Is Superior With a Centralized Approach.
Chest. 2022 Mar;161(3):818-825. doi: 10.1016/j.chest.2021.09.002. Epub 2021 Sep 15.
8
Implementing lung cancer screening in primary care: needs assessment and implementation strategy design.
Transl Behav Med. 2022 Feb 16;12(2):187-197. doi: 10.1093/tbm/ibab115.
9
Lung cancer screening in Europe: where are we in 2021?
Transl Lung Cancer Res. 2021 May;10(5):2407-2417. doi: 10.21037/tlcr-20-890.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验